Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Pharmacokinetics
Erschienen in: Clinical Pharmacokinetics 2/2016

01.02.2016 | Review Article

Alternative Sampling Strategies for Cytochrome P450 Phenotyping

verfasst von: Pieter M. M. De Kesel, Willy E. Lambert, Christophe P. Stove

Erschienen in: Clinical Pharmacokinetics | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Interindividual variability in the expression and function of drug metabolizing cytochrome P (CYP) 450 enzymes, determined by a combination of genetic, non-genetic and environmental parameters, is a major source of variable drug response. Phenotyping by administration of a selective enzyme substrate, followed by the determination of a specific phenotyping metric, is an appropriate approach to assess the in vivo activity of CYP450 enzymes as it takes into account all influencing factors. A phenotyping protocol should be as simple and convenient as possible. Typically, phenotyping metrics are determined in traditional matrices, such as blood, plasma or urine. Several sampling strategies have been proposed as an alternative for these traditional sampling techniques. In this review, we provide a comprehensive overview of available methods using dried blood spots (DBS), hair, oral fluid, exhaled breath and sweat for in vivo CYP450 phenotyping. We discuss the relation between phenotyping metrics measured in these samples and those in conventional matrices, along with the advantages and limitations of the alternative sampling techniques. Reliable phenotyping procedures for several clinically relevant CYP450 enzymes, including CYP1A2, CYP2C19 and CYP2D6, are currently available for oral fluid, breath or DBS, while additional studies are needed for other CYP450 isoforms, such as CYP3A4. The role of hair analysis for this purpose remains to be established. Being non- or minimally invasive, these sampling strategies provide convenient and patient-friendly alternatives for classical phenotyping procedures, which may contribute to the implementation of CYP450 phenotyping in clinical practice.
Literatur
1.
Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001;14(6):611–50.PubMedCrossRef
2.
3.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.PubMedCrossRef
4.
Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193–200.PubMedCrossRef
5.
Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18):2270–9.PubMedCrossRef
6.
Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013;17(3):165–84.PubMedCentralPubMedCrossRef
7.
Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 2003;17(1):27–41.PubMedCrossRef
8.
Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211–21.PubMedCrossRef
9.
10.
11.
Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10(3):187–216.PubMedCrossRef
12.
Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther. 2007;81(2):270–83.PubMedCrossRef
13.
Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics. 1996;6(2):159–76.PubMedCrossRef
14.
Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998;8(5):403–10.PubMedCrossRef
15.
Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338–43.PubMed
16.
Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009;31(3):327–36.PubMedCrossRef
17.
Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet. 2014;53(11):961–73.PubMedCentralPubMedCrossRef
18.
Stove CP, Ingels AS, De Kesel PM, Lambert WE. Dried blood spots in toxicology: from the cradle to the grave? Crit Rev Toxicol. 2012;42(3):230–43.PubMedCrossRef
19.
Sadones N, Capiau S, De Kesel PM, Lambert WE, Stove CP. Spot them in the spot: analysis of abused substances using dried blood spots. Bioanalysis. 2014;6(17):2211–27.PubMedCrossRef
20.
Barfield M, Spooner N, Lad R, Parry S, Fowles S. Application of dried blood spots combined with HPLC-MS/MS for the quantification of acetaminophen in toxicokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;870(1):32–7.PubMedCrossRef
21.
Xu Y, Woolf EJ, Agrawal NG, Kothare P, Pucci V, Bateman KP. Merck’s perspective on the implementation of dried blood spot technology in clinical drug development: why, when and how. Bioanalysis. 2013;5(3):341–50.PubMedCrossRef
22.
Suresh PS, Kumar SV, Kumar A, Mullangi R. Development of an LC-MS/MS method for determination of bicalutamide on dried blood spots: application to pharmacokinetic study in mice. Biomed Chromatogr. 2015;29(2):254–60.CrossRef
23.
Ingels AS, Hertegonne K, Lambert WE, Stove CP. Feasibility of following up gamma-hydroxybutyric acid concentrations in sodium oxybate (Xyrem®)-treated narcoleptic patients using dried blood spot sampling at home: an exploratory study. CNS Drugs. 2013;27(3):233–7.PubMedCrossRef
24.
Bowen CL, Hemberger MD, Kehler JR, Evans CA. Utility of dried blood spot sampling and storage for increased stability of photosensitive compounds. Bioanalysis. 2010;2(11):1823–8.PubMedCrossRef
25.
Bowen CL, Volpatti J, Cades J, Licea-Perez H, Evans CA. Evaluation of glucuronide metabolite stability in dried blood spots. Bioanalysis. 2012;4(23):2823–32.PubMedCrossRef
26.
D’Arienzo CJ, Ji QC, Discenza L, et al. DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors. Bioanalysis. 2010;2(8):1415–22.PubMedCrossRef
27.
Faller A, Richter B, Kluge M, Koenig P, Seitz HK, Skopp G. Stability of phosphatidylethanol species in spiked and authentic whole blood and matching dried blood spots. Int J Legal Med. 2013;127(3):603–10.PubMedCrossRef
28.
29.
Déglon J, Thomas A, Daali Y, Lauer E, Samer C, Desmeules J, et al. Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite. J Pharm Biomed Anal. 2011;54(2):359–67.PubMedCrossRef
30.
Ooms JA, Knegt L, Koster EH. Exploration of a new concept for automated dried blood spot analysis using flow-through desorption and online SPE-MS/MS. Bioanalysis. 2011;3(20):2311–20.PubMedCrossRef
31.
Oliveira RV, Henion J, Wickremsinhe E. Fully-automated approach for online dried blood spot extraction and bioanalysis by two-dimensional-liquid chromatography coupled with high-resolution quadrupole time-of-flight mass spectrometry. Anal Chem. 2014;86(2):1246–53.PubMedCrossRef
32.
Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Tarning J, McGready R, et al. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2010;66(7):705–12.PubMedCentralPubMedCrossRef
33.
Mohammed BS, Cameron GA, Cameron L, Hawksworth GH, Helms PJ, Mclay JS. Can finger-prick sampling replace venous sampling to determine the pharmacokinetic profile of oral paracetamol? Brit J Clin Pharmacol. 2010;70(1):52–6.CrossRef
34.
35.
De Kesel PM, Sadones N, Capiau S, Lambert WE, Stove CP. Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions. Bioanalysis. 2013;5(16):2023–41.PubMedCrossRef
36.
Lad R. Validation of individual quantitative methods for determination of cytochrome P450 probe substrates in human dried blood spots with HPLC-MS/MS. Bioanalysis. 2010;2(11):1849–61.PubMedCrossRef
37.
de Boer T, Wieling J, Meulman E, Reuvers M, Renkema G, den Daas I, et al. Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed Chromatogr. 2011;25(10):1112–23.PubMedCrossRef
38.
Daali Y, Samer C, Déglon J, Thomas A, Chabert J, Rebsamen M, et al. Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin Pharmacol Ther. 2012;91(3):489–96.PubMedCrossRef
39.
Murphy SE, Wickham KM, Lindgren BR, Spector LG, Joseph A. Cotinine and trans 3′-hydroxycotinine in dried blood spots as biomarkers of tobacco exposure and nicotine metabolism. J Expo Sci Environ Epidemiol. 2013;23(5):513–8.PubMedCentralPubMedCrossRef
40.
De Kesel PM, Lambert WE, Stove CP. CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma. Bioanalysis. 2014;6(22):3011–24.PubMedCrossRef
41.
De Kesel PM, Lambert WE, Stove CP. Why dried blood spots are an ideal tool for CYP1A2 phenotyping. Clin Pharmacokinet. 2014;53(8):763–71.PubMedCrossRef
42.
Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L, Krahenbuhl S, et al. The Basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet. 2014;53(3):271–82.PubMedCrossRef
43.
Bosilkovska M, Déglon J, Samer C, Walder B, Desmeules J, Staub C, et al. Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis. 2014;6(2):151–64.PubMedCrossRef
44.
Bosilkovska M, Samer CF, Déglon J, Rebsamen M, Staub C, Dayer P, et al. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014;96(3):349–59.PubMedCentralPubMedCrossRef
45.
Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta. 2006;370(1–2):17–49.PubMedCrossRef
46.
Barbosa J, Faria J, Carvalho F, Pedro M, Queriós O, Moreira R, et al. Hair as an alternative matrix in bioanalysis. Bioanalysis. 2013;5(8):895–914.PubMedCrossRef
47.
LeBeau M, Montgomery MA, Brewer JD. The role of variations in growth rate and sample collection on interpreting results of segmental analyses of hair. Forensic Sci Int. 2011;210(1–3):110–6.PubMedCrossRef
48.
Cooper GA, Kronstrand R, Kintz P. Society of Hair Testing guidelines for drug testing in hair. Forensic Sci Int. 2012;218(1–3):20–4.PubMedCrossRef
49.
Agius R, Kintz P. Guidelines for European workplace drug and alcohol testing in hair. Drug Test Anal. 2010;2(8):367–76.PubMedCrossRef
50.
Madry MM, Rust KY, Guglielmello, Baumgartner MR, Kraemer T. Metabolite to parent drug concentration ratios in hair for the differentiation of tramadol intake from external contamination and passive exposure. Forensic Sci Int. 2012;223(1–3):330–4.PubMedCrossRef
51.
Poetzsch M, Baumgartner MR, Steuer AE, Kraemer T. Segmental hair analysis for differentiation of tilidine intake from external contamination using LC-ESI-MS/MS and MALDI-MS/MS imaging. Drug Test Anal. 2015;7(2):143–9.PubMedCrossRef
52.
Jurado C, Kintz P, Menéndez M, Repetto M. Influence of the cosmetic treatment of hair on drug testing. Int J Legal Med. 1997;110(3):159–63.PubMedCrossRef
53.
Mizuno A, Uematsu T, Gotoh S, Katoh E, Nakashima M. The measurement of caffeine concentration in scalp hair as an indicator of liver function. J Pharm Pharmacol. 1996;48(6):660–4.PubMedCrossRef
54.
Thieme D, Rolf B, Sachs H, Schmid D. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med. 2008;122(2):149–55.PubMedCrossRef
55.
De Kesel PM, Lambert WE, Stove CP. Paraxanthine/caffeine concentration ratios in hair: an alternative for plasma-based phenotyping of cytochrome P450 1A2? Clin Pharmacokinet. 2015;54(7):771–81.PubMedCrossRef
56.
Klein J, Blanchette P, Koren G. Assessing nicotine metabolism in pregnancy: a novel approach using hair analysis. Forensic Sci Int. 2004;145(2–3):191–4.PubMedCrossRef
57.
Dempsey D, Jacob P 3rd, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther. 2002;301(2):594–8.PubMedCrossRef
58.
Koren G, Blanchette P, Lubetzky A, Kramer M. Hair nicotine:cotinine metabolic ratio in pregnant women: a new method to study metabolism in late pregnancy. Ther Drug Monit. 2008;30(2):246–8.PubMedCrossRef
59.
O’Brien L, Baumer C, Thieme D, Sachs H, Koren G. Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach. Forensic Sci Int. 2010;196(1–3):93–6.PubMedCrossRef
60.
Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002;72(2):184–91.PubMedCrossRef
61.
Tracy TS, Venkataramanan R, Glover DD, Caritis SN. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633–9.PubMedCrossRef
62.
Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989–1008.PubMedCrossRef
63.
Jeong H. Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol. 2010;6(6):689–99.PubMedCentralPubMedCrossRef
64.
Himes SK, Goodwin RS, Rock CM, Jones HE, Johnson RE, Wilkins DG, et al. Methadone and metabolites in hair of methadone-assisted pregnant women and their infants. Ther Drug Monit. 2012;34(3):337–44.PubMedCentralPubMedCrossRef
65.
Rostami-Hodjegan A, Wolff K, Hay AW, Raistrick D, Calvert R, Tucker GT. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol. 1999;48(1):43–52.PubMedCentralPubMedCrossRef
66.
Henderson GL. Mechanisms of drug incorporation into hair. Forensic Sci Int. 1993;63(1–3):19–29.PubMedCrossRef
67.
Langman LJ. The use of oral fluid for therapeutic drug management: clinical and forensic toxicology. Ann N Y Acad Sci. 2007;1098:145–66.PubMedCrossRef
68.
69.
Tsanaclis LM, Wicks JF, Chasin AA. Workplace drug testing, different matrices different objectives. Drug Test Anal. 2012;4(2):83–8.PubMedCrossRef
70.
Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med. 2004;42(11):1273–87.PubMedCrossRef
71.
Mullangi R, Agrawal S, Srinivas NR. Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives. Biomed Chromatogr. 2009;23(1):3–25.PubMedCrossRef
72.
Wille SM, Baumgartner MR, Fazio VD, Samyn N, Kraemer T. Trends in drug testing in oral fluid and hair as alternative matrices. Bioanalysis. 2014;6(17):2193–209.PubMedCrossRef
73.
Zylber-Katz E, Granit L, Levy M. Relationship between caffeine concentrations in plasma and saliva. Clin Pharmacol Ther. 1984;36(1):133–7.PubMedCrossRef
74.
Jost G, Wahlländer A, von Mandach U, Preisig R. Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology. 1987;7(2):338–44.PubMedCrossRef
75.
Setchell KD, Welsh MB, Klooster MJ, Balistreri WF, Lim CK. Rapid high-performance liquid chromatography assay for salivary and serum caffeine following an oral load. An indicator of liver function. J Chromatogr. 1987;385:267–74.PubMedCrossRef
76.
Bianchetti MG, Kraemer R, Passweg J, Jost J, Preisig R. Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 1988;7(5):688–93.PubMedCrossRef
77.
Wahlländer A, Mohr S, Paumgartner G. Assessment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatol. 1990;10(2):129–37.PubMedCrossRef
78.
Lewis FW, Rector WG Jr. Caffeine clearance in cirrhosis. The value of simplified determinations of liver metabolic capacity. J Hepatol. 1992;14(2–3):157–62.PubMedCrossRef
79.
Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993;35(4):431–6.PubMedCentralPubMedCrossRef
80.
Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics. 1994;4(3):109–16.PubMedCrossRef
81.
Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics. 1996;6(2):121–49.PubMedCrossRef
82.
Spigset O, Hägg S, Söderström E, Dahlqvist R. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics. 1999;9(3):409–12.PubMedCrossRef
83.
Akinyinka OO, Sowunmi A, Honeywell R, Renwick AG. The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. Eur J Clin Pharmacol. 2000;56(2):159–65.PubMedCrossRef
84.
Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit. 2000;22(4):409–17.PubMedCrossRef
85.
Shirley KL, Hon YY, Penzak SR, Lam YW, Spratlin V, Jann MW. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology. 2003;28(5):961–6.PubMed
86.
Kukongviriyapan V, Senggunprai L, Prawan A, Gaysornsiri D, Kukongviriyapan U, Aiemsa-Ard J. Salivary caffeine metabolic ratio in alcohol-dependent subjects. Eur J Clin Pharmacol. 2004;60(2):103–7.PubMedCrossRef
87.
Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol. 2011;63(9):1161–8.PubMedCrossRef
88.
El-Yazigi A, Shabib S, Al-Rawithi S, Yusuf A, Legayada ES, Al-Humidan A. Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases. J Clin Pharmacol. 1999;39(4):366–72.PubMedCrossRef
89.
Tantcheva-Poór I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics. 1999;9(2):131–44.PubMed
90.
Forsyth JT, Grünewald RA, Rostami-Hodjegan A, Lennard MS, Sagar HJ, Tucker GT. Parkinson’s disease and CYP1A2 activity. Br J Clin Pharmacol. 2000;50(4):303–9.PubMedCentralPubMedCrossRef
91.
Zaigler M, Rietbrock S, Szymanski J, Dericks-Tan JS, Staib AH, Fuhr U. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Int J Clin Pharmacol Ther. 2000;38(5):235–44.PubMedCrossRef
92.
Hägg S, Spigset O, Lakso HA, Dahlqvist R. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol. 2001;57(6–7):493–7.PubMed
93.
Murray S, Lake BG, Gray S, Edwards AJ, Springall C, Bowey EA, et al. Effect of cruciferous vegetable consumption on heterocyclic aromatic amine metabolism in man. Carcinogenesis. 2001;22(9):1413–20.PubMedCrossRef
94.
Tantcheva-Poór I, Servera-Llaneras M, Scharffetter-Kochanek K, Fuhr U. Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients. Br J Dermatol. 2001;144(6):1127–32.PubMedCrossRef
95.
Bozikas VP, Papakosta M, Niopas I, Karavatos A, Mirtsou-Fidani V. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol. 2004;14(1):39–44.PubMedCrossRef
96.
Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2009;67(1):29–37.PubMedCentralPubMedCrossRef
97.
Perera V, Gross AS, McLachlan AJ. Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry. Clin Pharmacol Ther. 2012;92(4):511–9.PubMed
98.
Perera V, Gross AS, McLachlan AJ. Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans. J Pharm Pharmacol. 2013;65(2):264–70.PubMedCrossRef
99.
Hou ZY, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther. 1991;49(4):410–9.PubMedCrossRef
100.
Hou ZY, Chen CP, Yang WC, Lai MD, Buchert ET, Chung HM, et al. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis. Clin Pharmacol Ther. 1996;59(4):411–7.PubMedCrossRef
101.
Hu OY, Tang HS, Lane HY, Chang WH, Hu TM. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther. 1998;285(3):955–60.PubMed
102.
Lutz U, Völkel W, Lutz RW, Lutz WK. LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813(1–2):217–25.PubMedCrossRef
103.
Kuo BP, Hu OY, Hsiong CH, Pao LH, Chen TS, Hung CF. Single-point plasma or urine dextromethorphan method for determining CYP3A activity. Biopharm Drug Dispos. 2003;24(9):367–73.PubMedCrossRef
104.
Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, et al. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol. 2008;66(4):473–84.PubMedCentralPubMedCrossRef
105.
Kim I, Wtsadik A, Choo RE, Jones HE, Huestis MA. Usefulness of salivary trans-3′-hydroxycotinine concentration and trans-3′-hydroxycotinine/cotinine ratio as biomarkers of cigarette smoke in pregnant women. J Anal Toxicol. 2005;29(7):689–95.PubMedCrossRef
106.
West O, Hajek P, McRobbie H. Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. Psychopharmacology. 2011;218(2):313–22.PubMedCrossRef
107.
108.
Rubinstein ML, Shiffman S, Moscicki AB, Rait MA, Sen S, Benowitz NL. Nicotine metabolism and addiction among adolescent smokers. Addiction. 2013;108(2):406–12.PubMedCentralPubMedCrossRef
109.
Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, et al. Biomarkers for smoking cessation. Clin Pharmacol Ther. 2013;93(6):526–38.PubMedCentralPubMedCrossRef
110.
Carpenter MJ, Jardin BF, Burris JL, Mathew AR, Schnoll RA, Rigotti NA, et al. Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. Drugs. 2013;73(5):407–26.PubMedCentralPubMedCrossRef
111.
Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1):64–72.PubMedCrossRef
112.
St. Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P 3rd, Aziziyeh A, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1105–14.
113.
Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol. 2006;30(6):386–9.PubMedCrossRef
114.
Armuzzi A, Candelli M, Zocco MA, Andreoli A, De Lorenzo A, Nista EC, et al. Review article: breath testing for human liver function assessment. Aliment Pharmacol Ther. 2002;16(12):1977–96.PubMedCrossRef
115.
Nista EC, Fini L, Armuzzi A, Candelli M, Zocco MA, Cazzato IA, et al. 13C-breath tests in the study of microsomal liver function. Eur Rev Med Pharmacol Sci. 2004;8(1):33–46.PubMed
116.
Braden B, Lembcke B, Kuker W, Caspary WF. 13C-breath tests: current state of the art and future directions. Dig Liver Dis. 2007;39(9):795–805.PubMedCrossRef
117.
Modak AS. 13C breath tests in personalized medicine: fiction or reality? Expert Rev Mol Diagn. 2009;9(8):805–15.PubMedCrossRef
118.
Modak AS. Regulatory issues on breath tests and updates of recent advances on [13C]-breath tests. J Breath Res. 2013;7(3):037103.PubMedCrossRef
119.
Opdam FL, Modak AS, Gelderblom H, Guchelaar HJ. Breath tests to phenotype drug disposition in oncology. Clin Pharmacokinet. 2013;52(11):919–26.PubMedCrossRef
120.
Afolabi P, Wright M, Wootton SA, Jackson AA. Clinical utility of 13C-liver-function breath tests for assessment of hepatic function. Dig Dis Sci. 2013;58(1):33–41.PubMedCrossRef
121.
Pijls KE, de Vries H, Nikkessen S, Bast A, Wodzig WK, Koek GH. Critical appraisal of 13C breath tests for microsomal liver function: aminopyrine revisited. Liver Int. 2014;34(4):487–94.PubMedCrossRef
122.
Niwa T, Sato R, Yabusaki Y, Ishibashi F, Katagiri M. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999;29(2):187–93.PubMedCrossRef
123.
Kodaira C, Uchida S, Yamade M, Nishino M, Ikuma M, Namiki N, et al. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [13C]-aminopyrine breath test. J Clin Pharmacol. 2012;52(3):432–9.PubMedCrossRef
124.
Desta Z, Modak A, Nguyen PD, Lemler SM, Kurogi Y, Li L, et al. Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. J Pharmacol Exp Ther. 2009;329(1):297–305.PubMedCentralPubMedCrossRef
125.
Furuta T, Kodaira C, Nishino M, Yamade M, Sugimoto M, Ikuma M, et al. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Aliment Pharmacol Ther. 2009;30(3):294–300.PubMedCrossRef
126.
Furuta T, Iwaki T, Umemura K. [13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel. Eur J Clin Pharmacol. 2010;66(5):457–63.PubMedCrossRef
127.
Thacker DL, Modak A, Nguyen PD, Flockhart DA, Desta Z. Stereoselective pharmacokinetics of stable isotope (+/−)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity. Chirality. 2011;23(10):904–9.PubMedCentralPubMedCrossRef
128.
Tazaki J, Jinnai T, Tada T, Kato Y, Makiyama T, Ikeda T, et al. Prediction of clopidogrel low responders by a rapid CYP2C19 activity test. J Atheroscler Thromb. 2012;19(2):186–93.PubMedCrossRef
129.
Thacker DL, Modak A, Flockhart DA, Desta Z. Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? J Breath Res. 2013;7(1):016001.PubMedCentralPubMedCrossRef
130.
Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI. Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol. 2008;48(9):1041–51.PubMedCrossRef
131.
Opdam FL, Dezentje VO, den Hartigh J, Modak AS, Vree R, Batman E, et al. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. Cancer Chemother Pharmacol. 2013;71(3):593–601.PubMedCrossRef
132.
Park GJ, Katelaris PH, Jones DB, Seow F, Le Couteur DG, Ngu MC. Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology. 2003;38(5):1227–36.PubMedCrossRef
133.
Kotake AN, Schoeller DA, Lambert GH, Baker AL, Schaffer DD, Josephs H. The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther. 1982;32(2):261–9.PubMedCrossRef
134.
Lambert GH, Schoeller DA, Humphrey HE, Kotake AN, Lietz H, Campbell M, et al. The caffeine breath test and caffeine urinary metabolite ratios in the Michigan cohort exposed to polybrominated biphenyls: a preliminary study. Environ Health Perspect. 1990;89:175–81.PubMedCentralPubMedCrossRef
135.
Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, Roots I. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1992;52(2):170–80.PubMedCrossRef
136.
Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther. 1994;55(4):402–11.PubMedCrossRef
137.
Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther. 1995;57(1):16–24.PubMedCrossRef
138.
Kinirons MT, O’Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther. 1999;66(3):224–31.PubMedCrossRef
139.
Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther. 2004;76(4):341–9.PubMedCrossRef
140.
Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther. 2008;84(6):704–9.PubMedCrossRef
141.
Kurnik D, Wood AJ, Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther. 2006;80(3):228–34.PubMedCrossRef
142.
Mena-Bravo A, Luque de Castro MD. Sweat: a sample with limited present applications and promising future in metabolomics. J Pharm Biomed Anal. 2014;90:139–47.PubMedCrossRef
143.
Skopp G, Pötsch L. Perspiration versus saliva: basic aspects concerning their use in roadside drug testing. Int J Legal Med. 1999;112(4):213–21.PubMedCrossRef
144.
Cone EJ. Legal, workplace, and treatment drug testing with alternate biological matrices on a global scale. Forensic Sci Int. 2001;121(1–2):7–15.PubMedCrossRef
145.
De Giovanni N, Fucci N. The current status of sweat testing for drugs of abuse: a review. Curr Med Chem. 2013;20(4):545–61.PubMed
146.
Delahunty T, Schoendorfer D. Caffeine demethylation monitoring using a transdermal sweat patch. J Anal Toxicol. 1998;22(7):596–600.PubMedCrossRef
147.
Kuwayama K, Tsujikawa K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H. Time-course measurements of caffeine and its metabolites extracted from fingertips after coffee intake: a preliminary study for the detection of drugs from fingerprints. Anal Bioanal Chem. 2013;405(12):3945–52.PubMedCrossRef
148.
Grosso LM, Triche EW, Belanger K, Benowitz NL, Holford TR, Bracken MB. Caffeine metabolites in umbilical cord blood, cytochrome P-450 1A2 activity, and intrauterine growth restriction. Am J Epidemiol. 2006;163(11):1035–41.PubMedCrossRef
149.
Metadaten
Titel
Alternative Sampling Strategies for Cytochrome P450 Phenotyping
verfasst von
Pieter M. M. De Kesel
Willy E. Lambert
Christophe P. Stove
Publikationsdatum
01.02.2016
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 2/2016
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-015-0306-y

Weitere Artikel der Ausgabe 2/2016

Clinical Pharmacokinetics 2/2016 Zur Ausgabe

Original Research Article

Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch

Review Article

Challenges Associated with Route of Administration in Neonatal Drug Delivery

Original Research Article

Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus

Original Research Article

Effects of Cytochrome P450 3A4 Inhibitors—Ketoconazole and Erythromycin—on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions

Review Article

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

Original Research Article

Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-β1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants